All research is supported by internal funds from the Weatherhead PET Center, McGovern Medical School, University of Texas Health Science Center, Houston, Texas. No authors have relationships with any industry related to this manuscript. Drs Gould and Johnson have donated any personal honoraria for speaking engagements from Bracco Diagnostics and CDL Nuclear Technologies, commercial providers of nuclear cardiology products, to UTHealth. In addition, Dr Johnson serves as the principal investigator for the PET core laboratory of the randomized trial COSIRA-2 (Coronary sinus reducer in patients with refractory angina II) (https://www.clinicaltrials.gov; Unique identifier: NCT05102019), for which UTHealth receives support from Neovasc, Inc/Shockwave Medical. Dr Gould receives internal funding from the Weatherhead PET Center and is the applicant for 510(k) FDA-cleared K231731 PET software. To avoid conflict of interest, Dr Gould waived his rights to the royalties eligible to be received from sales of the intellectual property licensed by UTHealth to third parties. UTHealth approved his request to redirect all derived royalties to student scholarships or UTHealth’s Weatherhead PET Center research. UTHealth has a financial interest in intellectual property via its affiliation with UTHealth’s Weatherhead PET Imaging Center. A. Roby reports no conflicts.